VivoSim Labs, Inc.

VIVS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2012 FY2011 FY2010
Operating Activities
Net Income $-34.8M $-38.4M $-38.6M $-30.1M $-25.8M $-43.6M $-4.4M $-1.3M
Depreciation & Amortization $1.3M $1.1M $815.0K $472.0K $387.0K $195.0K $68.0K $59.0K
Depreciation $1.3M $1.1M $805.0K $464.0K $380.0K $188.0K $63.0K $57.0K
Amortization — — — — — — — $1.5K
Stock-Based Compensation $6.9M $7.4M $8.6M $7.0M $4.6M $1.4M $9.0K $4.0K
Net Cash from Operating Activities $-28.9M $-29.2M $-29.4M $-19.6M $-15.6M $-9.7M $-1.9M $-820.0K
Investing Activities
Capital Expenditures $226.0K $1.4M $2.1M $1.5M $277.0K $357.0K $46.0K $48.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-292.0K — — — — $-445.0K $-111.0K $-53.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $10.1M — — — — $24.6M $2.1M $1.0M
Net Change in Cash $-19.0M $660.0K $11.9M $2.0M $32.5M $14.5M $55.0K $144.0K
Free Cash Flow $-29.1M $-30.5M $-31.5M $-21.1M $-15.8M $-10.1M $-2.0M $-868.0K
← Newer Page 2 of 2 Older →